Favorable Media Coverage Somewhat Unlikely to Affect Antares Pharma (ATRS) Share Price

Media coverage about Antares Pharma (NASDAQ:ATRS) has trended positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Antares Pharma earned a daily sentiment score of 0.32 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 45.7341375703336 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

A number of equities research analysts have recently issued reports on the company. BidaskClub lowered Antares Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright set a $4.00 target price on Antares Pharma and gave the company a “buy” rating in a research note on Tuesday, March 27th. Finally, ValuEngine lowered Antares Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $3.94.

How to Become a New Pot Stock Millionaire

Shares of ATRS stock traded up $0.05 during trading hours on Thursday, reaching $2.14. The company had a trading volume of 1,710,049 shares, compared to its average volume of 1,392,676. Antares Pharma has a twelve month low of $1.58 and a twelve month high of $4.09. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.94 and a current ratio of 3.53. The firm has a market cap of $321.42, a P/E ratio of -19.45 and a beta of 0.21.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Tuesday, March 13th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 44.29% and a negative net margin of 30.71%. The firm had revenue of $14.00 million during the quarter, compared to analyst estimates of $15.44 million. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. equities research analysts predict that Antares Pharma will post -0.07 EPS for the current year.

WARNING: This piece of content was reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://baseballnewssource.com/2018/04/05/favorable-media-coverage-somewhat-unlikely-to-impact-antares-pharma-atrs-stock-price-2/2027700.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.